Diagnóstico y tratamiento actualizado | 28 SEP 16

Accidente cerebrovascular

La última década ha sido testigo de avances extraordinarios en el tratamiento y la prevención del ACV.
Autor/a: Graeme J Hankey The Lancet -13 September 2016
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas


1 Feigin VL, Forouzanfar MH, Krishnamurthi R, for the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990–2010: findings from the

Global Burden of Disease Study 2010. Lancet 2014; 383: 245–54.

2 Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al, for the Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010), for the GBD Stroke Experts Group. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013; 1: e259–81.

3 Sacco RL, Kasner SE, Broderick JP, et al. An updated defi nition of stroke for the 21st century: a statement for healthcare professionals

from the American Heart Association/American Stroke Association. Stroke 2013; 44: 2064–89.

4 Hankey GJ, Blacker DJ. Is it a stroke? BMJ 2015; 350: h56.

5 Whiteley WN, Wardlaw JM, Dennis MS, Sandercock PA. Clinical scores for the identifi cation of stroke and transient ischaemic attack in the emergency department: a cross-sectional study. J Neurol Neurosurg Psychiatry 2011; 82: 1006–10.

6 Brunser AM, Hoppe A, Illanes S, et al. Accuracy of diff usionweighted imaging in the diagnosis of stroke in patients with suspected cerebral infarct. Stroke 2013; 44: 1169–71.

7 Brazzelli M, Chappell FM, Miranda H, et al. Diff usion-weighted imaging and diagnosis of transient ischemic attack. Ann Neurol 2014; 75: 67–76.

8 Gibson LM, Whiteley W. The diff erential diagnosis of suspected stroke: a systematic review. J R Coll Physicians Edinb 2013; 43: 114–48.

9 Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classifi cation and natural history of clinically identifi able subtypes of cerebral infarction. Lancet 1991; 337: 1521–26.

10 Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classifi cation of subtype of acute ischemic stroke. Defi nitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35–41.

11 Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). Cerebrovasc Dis 2013; 36: 1–5.

12 Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classifi cation of ischemic stroke: the Causative Classifi cation of Stroke System. Stroke 2007; 38: 2979–84.

13 Hart RG, Diener HC, Coutts SB, et al, and the Cryptogenic Stroke/ESUS International Working roup. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014; 13: 429–38.

14 Rannikmae L, Woodfi eld R, Anderson CS, et al. Reliability of intracerebral haemorrhage classifi cation systems: a systematic review. Int J Stroke 2016; 11: 626–36.

15 Xie X, Atkins E, Lv J, et al. Eff ects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387: 435–43.

16 Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the effi cacy and safety of statin therapy. Lancet 2016; published online Sept 8. http://dx.doi.org/10.1016/S0140-6736(16)31357-5.

17 Raman G, Moorthy D, Hadar N, et al. Management strategies for asymptomatic carotid stenosis: a systematic review and meta-analysis. Ann Intern Med 2013; 158: 676–85.

18 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fi brillation. Ann Intern Med 2007; 146: 857–67.

19 Mons U, Muezzinler A, Gellert C, et al, for the CHANCES Consortium. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 2015; 350: h1551.

20 Zhang C, Qin YY, Chen Q, et al. Alcohol intake and risk of stroke: a dose response meta-analysis of prospective studies. Int J Cardiol 2014; 174: 669–77.

21 Kernan WN, Viscoli CM, Furie KL, et al, for the IRIS Trial Investigators. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 2016; 374: 1321–31.

22 Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. Lancet 2014; 383: 1973–80.

23 O’Donnell MJ, Chin SL, Rangarajan S, et al, for the INTERSTROKE investigators. Global and regional eff ects of potentially modifi able risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; 388: 761–75.

24 Feigin VL, Roth GA, Naghavi M, for the Global Burden of Diseases, Injuries and Risk Factors Study 2013 and Stroke Experts Writing Group. Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 2016; 15: 913–24.

25 NINDS Stroke Genetics Network (SiGN) and International Stroke Genetics Consortium. Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. Lancet Neurol 2016; 15: 174–84.

26 Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium; Stroke Genetics Network (SiGN); International Stroke Genetics Consortium (ISGC). Identifi cation of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2016; 15: 695–707.

27 Guiraud V, Amor MB, Mas JL, Touze E. Triggers of ischemic stroke: A systematic review. Stroke 2010; 41: 2669–77.

28 Luengo-Fernandez R, Paul NL, Gray AM, et al, for the Oxford Vascular Study. Population-based study of disability and institutionalization after transient ischemic attack and stroke: 10-year results of the Oxford Vascular Study. Stroke 2013; 44: 2854–61.

29 Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2014; 85: 660–67.

30 Ayis SA, Coker B, Rudd AG, Dennis MS, Wolfe CD. Predicting independent survival after stroke: a European study for the development and validation of standardised stroke scales and prediction models of outcome. J Neurol Neurosurg Psychiatry 2013; 84: 288–96.

31 Coull AJ, Lovett JK, Rothwell PM, for the Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004; 328: 326.

32 Kiyohara T, Kamouchi M, Kumai Y, et al, for the Fukuoka Stroke Registry Investigators. ABCD3 and ABCD3-I scores are superior to ABCD2 score in the prediction of short- and long-term risks of stroke after transient ischemic attack. Stroke 2014; 45: 418–25.

33 Arsava EM, Kim G-M, Oiverira-Filho J, et al. Prediction of Early Recurrence after Acute Ischemic Stroke. JAMA Neurol 2016; 73: 396–401.

34 Wardlaw JM, Brazzelli M, Chappell FM, et al. ABCD2 score and secondary stroke prevention: meta-analysis and eff ect per 1000 patients triaged. Neurology 2015; 85: 373–80.

35 Rothwell PM, Giles MF, Chandratheva A, et al. for the Early use of Existing Preventive Strategies for Stroke (EXPRESS) study. Eff ect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370: 1432–42.

36 Amarenco P, Lavallee PC, Labreuche J, et al, for the TIAregistry. org Investigators. One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. N Engl J Med 2016; 374: 1533–42.

37 Mohan KM, Wolfe CD, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 2011; 42: 1489–94.

38 Hijazi Z, Lindback J, Alexander JH, et al, for the ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fi brillation. Eur Heart J 2016; 37: 1582–90.

39 Biffi A, Anderson CD, Battey TW, et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA 2015; 314: 904–12.

40 Emberson J, Lees KR, Lyden P, et al, for the Stroke Thrombolysis Trialists’ Collaborative Group. Eff ect of treatment delay, age, and stroke severity on the eff ects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384: 1929–35.

41 Badhiwala JH, Nassiri F, Alhazzani W, et al. Endovascular thrombectomy for acute ischemic stroke: a meta-analysis. JAMA 2015; 314: 1832–43.

42 Goyal M, Menon BK, van Zwam WH, et al, for the HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from fi ve randomised trials. Lancet 2016; 387: 1723–31.

43 Sandercock PA, Counsell C, Tseng MC, Cecconi E. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2014; 3: CD000029.

44 Yang MH, Lin HY, Fu J, Roodrajeetsing G, Shi SL, Xiao SW. Decompressive hemicraniectomy in patients with malignant middle cerebral artery infarction: A systematic review and meta-analysis. Surgeon 2015; 13: 230–40.

45 Tsivgoulis G, Katsanos AH, Butcher KS, et al, Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis. Neurology 2014; 83: 1523–29.

46 Qureshi AI, Palesch YY, Barsan WG, et al, and the ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016 June 8. DOI:10.1056/NEJMoa1603460.

47 Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013; 382: 397–408.

48 Stroke Unit Trialists’ Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2013; 9: CD000197.

49 Strbian D, Michel P, Seiff ge DJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores. Stroke 2014; 45: 752–58.

50 Anderson CS, Robinson T, Lindley RI, et al, for the ENCHANTED Investigators and Coordinators. Low-Dose versus  standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med 2016; 374: 2313–23.

51 Schellinger PD, Alexandrov AV, Barreto AD, for the CLOTBUSTER Investigators. Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial. Int J Stroke

2015; 10: 1141–48.

52 Lyden PD, Hemmen TM, Grotta J, Rapp K, Raman R. Endovascular therapeutic hypothermia for acute ischemic stroke: ICTuS 2/3 protocol. Int J Stroke 2014; 9: 117–25.

53 Albers GW, von Kummer R, Truelsen T, et al, for the DIAS-3 Investigators. Safety and effi cacy of desmoteplase given 3–9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol 2015; 14: 575–84.

54 Huang X, MacIsaac R, Thompson JL, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke 2016; 11: 534–43.

55 Zinkstok SM, Roos YB, for the ARTIS investigators. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 2012; 380: 731–37.

56 Warach SJ, Luby M, Albers GW, et al, for the Stroke Imaging Research (STIR) and VISTA-Imaging Investigators. Acute stroke imaging research roadmap III imaging selection and outcomes in acute stroke reperfusion clinical trials: consensus recommendations and further research priorities. Stroke 2016; 47: 1389–98.

57 Goyal M, Yu AY, Menon BK, et al. Endovascular therapy in acute ischemic stroke: challenges and transition from trials to bedside. Stroke 2016; 47: 548–53.

58 Yuan ZH, Jiang JK, Huang WD, Pan J, Zhu JY, Wang JZ. A meta-analysis of the effi cacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosci 2010; 17: 685–93.

59 Baharoglu MI, Cordonnier C, Salman RA, and the PATCH Investigators. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016; 387: 2605–13.

60 Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824–36.

61 Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016; 15: 566–73.

62 Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511–520.

63 Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413–24.

64 Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant eff ect of edoxaban. N Engl J Med 2014; 371: 2141–42.

65 Aronis KN, Hylek EM. Who, when, and how to reverse non-vitamin K oral anticoagulants. J Thromb Thrombolysis 2016; 41: 253–72.

66 Gregson BA, Broderick JP, Auer LM, et al. Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage. Stroke 2012; 43: 1496–504.

67 Mould WA, Carhuapoma JR, Muschelli J, et al. Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke 2013; 44: 627–34.

68 Ziai WC, Tuhrim S, Lane K, for the CLEAR III Investigators. A multicenter, randomized, double-blinded, placebo-controlled phase III study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III). Int J Stroke 2014; 9: 536–42.

69 Bray BD, Ayis S, Campbell J, et al. Associations between the organisation of stroke services, process of care, and mortality in England: prospective cohort study. BMJ 2013; 346: f2827.

70 Langhorne P, de Villiers L, Pandian JD. Applicability of stroke-unit care to low-income and middle-income countries. Lancet Neurol 2012; 11: 341–48.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2022